Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Targeted OncologyOpen Access

Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach

View Full Paper
Ask AI
Bookmark
Share

Authors

MEMohamed ElmeliegyPSPooneh SoltantabarJHJennifer Hibma

Discussion

Loading...

Member takes

Overview

Evaluation shows fixed dosing of elranatamab maintains safety and efficacy in multiple myeloma patients, indicating promising outcomes.

Key Points

  • Elranatamab fixed dosing exhibited consistent efficacy and safety across varying body weights in multiple myeloma patients.
  • Response rates were comparable across body weight quartiles, with no significant safety concerns noted.
  • Analysis of pharmacokinetics showed overlapping predose concentrations, ensuring effective treatment irrespective of weight.
  • Results support fixed dosing of elranatamab for relapsed or refractory multiple myeloma, addressing overdosing and underdosing issues.

Cite This Study

Elmeliegy et al. (2025) studied this question.

synapsesocial.com/papers/68af35ddcf1dd9ea359e9bffhttps://doi.org/10.1007/s11523-025-01170-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma2025
  2. 2Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma2025
  3. 3A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results2025 · 1 citations
  4. 4Real-world treatment patterns of elranatamab in patients with multiple myeloma in Japan: Findings from the EVEREST study2025
  5. 5Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025